VCIM
AVDL

Velan Capital Investment Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Velan Capital Investment Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100,000
Closed -$1.65M – 31
2023
Q2 		$1.65M Buy
100,000
+74,257
+288% +$965K 1.53% 21
2023
Q1 		$236K Buy
+25,743
New +$212K 0.2% 30

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Velan Capital Investment Management's AVDL Position: Q3 2023 in Review

Velan Capital Investment Management sold out of Avadel Pharmaceuticals (AVDL) in Q3 2023, closing a stake of 100,000 shares — an estimated $1.65M sold.

Velan Capital Investment Management first reported a position in AVDL in Q1 2023 and held it in 2 quarters. The position peaked at $1.65M in Q2 2023. 99 funds tracked by Wall St. Rank hold AVDL as of Q3 2023.

  • Velan Capital Investment Management reported no remaining Avadel Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Velan Capital Investment Management sold 100,000 Avadel Pharmaceuticals shares in Q3 2023, an estimated $1.65M.
  • Velan Capital Investment Management first reported a position in Avadel Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Velan Capital Investment Management's Avadel Pharmaceuticals position peaked at $1.65M in Q2 2023.
  • 99 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2023.

Based on Velan Capital Investment Management's 13F filing for Q3 2023, filed 13 Nov 2023.